Aging and inflammation in Hodgkin's lymphoma survivors
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how biological aging and inflammation affect people with Hodgkin's lymphoma who have finished their first treatment and are in remission. It may help doctors understand long-term health and follow-up needs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had Hodgkin's lymphoma that was stage IIB, III, or IV when first diagnosed.
- You have been in remission (no signs of cancer) for at least 2 years after your first therapy.
- Or, you have just been diagnosed with stage IIB, III, or IV Hodgkin's lymphoma and are about to start your first treatment.
- You are 18 years or older.
- You do not have another type of cancer right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a type of immune cell aging (called 'immunological senescence') might affect how well the drug pembrolizumab works in people whose Hodgkin lymphoma has come back or not responded to treatment.
This trial is looking at new ways to predict how Hodgkin lymphoma will respond to treatment. It collects blood and tumor samples at key times to see if these can help doctors make better treatment decisions in the future.
This study looks at how lymphoma treatment may affect thinking and memory years after therapy. It aims to understand and support long-term survivors.
This study looks at quality of life in people age 70 and older with slow-growing (low-grade) B-cell non-Hodgkin lymphoma who haven’t been treated yet. It requires a geriatric (aging-focused) check before starting care, to see what helps older patients feel better during treatment.
This trial tests a structured lifestyle and survivorship care plan for people who finished treatment for certain lymphoma types and are now in long-term remission. The goal is to support long-term health (including heart-related monitoring) and reduce future risks.
This study looks at blood (“hematopoietic”) information in people age 60+ with relapsed B-cell non-Hodgkin lymphoma who need an additional round of treatment. It may help researchers understand changes in the body during active lymphoma therapy.
Hear when a new Hodgkin Lymphoma in Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.